Publication | Open Access

PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)

HepatologyHepatitis CViral HepatitisPgi18 Cost-effectivenessAntiviral Drug DevelopmentHepatitisVirologyAntiviral TherapyChronic Viral InfectionAntiviral DrugMedicineChronic Hepatitis CGenotype 1